Mitsubishi Tanabe Pharma America, Inc. - Company Research Report

Company Overview

Name and Mission

• Company Name: Mitsubishi Tanabe Pharma America, Inc. (MTPA)

• Mission: Mitsubishi Tanabe Pharma America is dedicated to tackling seemingly insurmountable challenges to make a real difference in the lives of people struggling with debilitating diseases.

History and Founders

• Parent Company Founded: Mitsubishi Tanabe Pharma Corporation (MTPC) was founded in 1678.

Key People

• Vice President of Medical Affairs: Gustavo A. Suarez Zambrano, M.D.

• President of MTPA: Yasutoshi Kawakami

Headquarters

• Location: Jersey City, NJ, USA

Employees

• Number of Employees: Over 140 full-time employees in the USA

Revenue

• Revenue: No information is available

Notable Attributes

• Mitsubishi Tanabe Pharma America is known for developing scientific and medicinal options to help patients with serious and debilitating diseases, especially in the areas of neurological disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson’s disease.

Products and Services

Product Offerings

RADICAVA® (edaravone) and RADICAVA ORS® (edaravone)

• Description: These are treatments indicated for amyotrophic lateral sclerosis (ALS).

• Key Features:

• RADICAVA - Administered via intravenous (IV) infusion in 28-day cycles. Each 60 mg dose is given over 60 minutes.

• RADICAVA ORS - Oral formulation, taken daily, offers an alternative to the IV infusion, recognized for its significant contribution to patient care.

• Efficacy and Safety - Supported by multiple clinical trials, post-hoc analyses, and real-world evidence.

ND0612

• Description: An investigational drug-device combination therapy for Parkinson’s disease.

• Key Features:

• 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa, addressing motor fluctuations in Parkinson’s disease.

Recent Developments

New Products and Features

• RADICAVA ORS® (edaravone): Received FDA recognition for Orphan Drug Exclusivity due to its major contribution to patient care.

• Investigational ND0612: Studies continue to evaluate this therapy's safety and efficacy in Parkinson’s disease patients.

Strategic Collaborations

• Dewpoint Therapeutics Partnership: Research collaboration to develop a novel TDP-43 small molecule condensate modulator for ALS, aiming to address underlying ALS pathology.

Recent Studies and Presentations

• ALS Research Presentations: Participation in symposia like MNDA’s 35th International Symposium, where insights from preclinical, clinical, and real-world studies on RADICAVA® were shared.

• Phase 2b BeyoND Study: Presented 3-year outcomes of investigational ND0612 showing sustained reduction in daily OFF time for Parkinson’s disease.

Recent Achievements

• RADICAVA IV and RADICAVA ORS have been prescribed to over 16,000 ALS patients, highlighting the widespread clinical adoption and impact of these therapies on patient care.

Conclusion

This report highlights Mitsubishi Tanabe Pharma America's commitment to developing transformative medical treatments for serious diseases. Their focus on collaborations and research underscores their dedication to addressing unmet medical needs and pioneering therapeutic advancements, especially in neurological disorders like ALS and Parkinson’s disease.